BUZZ-OncoMed Pharmaceuticals: Set to open at 3-mth low after equity raise

** OncoMed Pharmaceuticals (NasdaqGS: OMED - news) down 15 pct premarket after cancer drug developer prices its follow-on launched after the bell Wed at a steep discount

** If losses hold, stock set to open at lowest levels since early May. On course for biggest one-day pct fall since Jan

** OncoMed offers 5.5 mln shares at $10.00, a 14.6-pct discount to stock's $11.71 last sale

** Deal represents about 18 pct of co's 30.84 mln shares outstanding as of end-Jun

** OncoMed expects to use offering proceeds along with cash on hand to fund its experimental immuno-oncology drug platform

** OMED has seven drug candidates in various stages of development. Has collaboration agreements with top shareholder GlaxoSmithKline (Other OTC: GLAXF - news) , as well as Bayer AG (LSE: 0P6S.L - news) and Celgene (Swiss: CELG.SW - news)

** YTD, OncoMed's stock has lost half its value, while the Nasdaq Biotech index has shed 14 pct